在罕见癌症中评估生物标志物向治疗的证据的标准-一个推断框架
Doah Cho1,2, Sarah J Lord3, Robyn Ward4
1National Health and Medical Research Council Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Australia.
Therapeutic advances in medical oncology
|September 4, 2024
概括
一个新的框架有助于评估在常见癌症中经过验证的向癌症疗法是否可以用于具有相同生物标志物的罕见癌症. 这有助于对罕见疾病治疗的透明决策.
科学领域:
- 在瘤学瘤学.
- 生物标志物发现发现
- 临床试验设计 临床试验设计
背景情况:
- 针对性治疗和瘤测序方面的进展正在创造更小,生物标志物定义的癌症类型.
- 随机对照试验 (RCT) 在罕见疾病中往往是不可行的,因此越来越依赖单臂研究.
- 从常见到罕见的癌症中推断治疗益处需要仔细考虑疾病和生物标志物的相似性.
研究的目的:
- 开发一个框架来评估生物标志物向疗法的证据推断.
- 引导从常见癌症RCT中获得的证据应用于与相同生物标志物共享的罕见癌症.
主要方法:
- 该框架是根据方法指南的范围审查的核心主题开发的.
- 监管机构 (EMA,FDA,MSAC) 的原则被纳入框架的设计.
- 该框架由一系列问题组成,涉及证据推断的基本标准.
主要成果:
- 提出了一个框架,用于评估常见癌症和罕见癌症之间疾病和治疗结果的相似性.
- 关键组成部分包括预后,生物标志物测试有效性,可操作性,治疗疗效和安全性.
- 识别的知识差距可以为未来的研究重点提供信息.
结论:
- 该框架使监管,报销和临床决策的系统评估和标准化成为可能.
- 它促进了参与罕见癌症药物评估的利益相关者之间的透明讨论.
- 这种方法支持对罕见的生物标志物定义癌症的基于证据的决策.
关键词:
由生物标志物驱动的试验.生物标志物指导治疗生物标志物 生物标志物临床试验是指临床试验中的临床试验.伴侣诊断系统 伴侣诊断系统预测性的生物标志物预后生物标志物 预后生物标志物生物标志物反应的生物标志物有针对性的治疗.更多相关视频
08:28Author Spotlight: Advancing Metabolomics Analysis of Rare Hematopoietic Stem Cells
Published on: February 23, 2024
1.9K
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
16.6K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K